Immatics Presents Clinical Activity and Response Dynamics of Anzu-cel PRAME Cell Therapy at 2026 ASCO Annual Meeting

Immatics announced extended Phase 1b data for anzu-cel (IMA203), a PRAME-directed TCR T-cell therapy, showing 56% confirmed objective response rate, 14.6 months median duration of response, and 16.2 months median overall survival in metastatic melanoma patients. The therapy demonstrated rapid, deep and durable anti-tumor activity with a manageable safety profile. The Phase 3 SUPRAME trial remains on track for BLA submission in H1 2027.

06/01/2026, 8:00 AM • GlobeNewswire

Synovial Sarcoma Clinical Trial Pipeline Accelerates as 15+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight

Over 15 pharmaceutical companies are actively developing more than 20 pipeline drugs for synovial sarcoma treatment, with promising therapies in various clinical trial stages. Key players including Takara Bio, Immatics, Moderna, Adaptimmune, and Zelluna are advancing innovative approaches such as TCR-T therapies and bispecific antibodies to address the significant unmet medical need in this rare cancer indication.

05/28/2026, 1:00 PM • GlobeNewswire

PRAME-directed Cell Therapy Using Immatics’ TCR Induces Deep and Durable Remission in Pediatric Patient with Advanced Metastatic Nephroblastoma

Immatics announced that a 17-year-old patient with advanced metastatic nephroblastoma achieved deep remission following treatment with a PRAME-directed TCR T-cell therapy. The patient, who had exhausted all available treatment options, experienced marked regression of liver, lung, and brain metastases with ongoing response at 6 months follow-up. The case will be presented at the AACR Annual Meeting 2026, supporting the therapeutic potential of PRAME TCR T-cell therapy in pediatric solid tumors.

04/17/2026, 3:00 PM • GlobeNewswire

Immatics Presents IMA203CD8 PRAME Cell Therapy Data from Ongoing Dose Escalation and Shows Promising Initial Anti-tumor Activity in PRAME-Positive Tumors at ESMO-IO 2025 Congress

Immatics reported promising initial anti-tumor activity for its second-generation PRAME cell therapy IMA203CD8 in a Phase 1a dose escalation trial, showing encouraging clinical responses across multiple cancer types, particularly in ovarian carcinoma.

12/11/2025, 7:00 AM • GlobeNewswire

Immatics Announces $125 Million Underwritten Offering

Immatics N.V. plans to sell 12.5 million ordinary shares at $10.00 per share, expecting to raise $125 million in a public offering managed by Jefferies, Leerink Partners, and Cantor.

12/05/2025, 6:00 AM • GlobeNewswire

Immatics Achieves Clinical Proof-of-Concept of its Next-Generation TCR Bispecific (TCER®) Pipeline with Data on IMA402 (PRAME) and IMA401 (MAGEA4/8) and Announces Next Development Steps

Immatics reported promising Phase 1a clinical trial results for two bispecific cancer therapies, IMA402 and IMA401, demonstrating favorable tolerability and deep, durable responses in heavily pre-treated patients with solid tumors across multiple cancer types.

11/12/2025, 7:00 AM • GlobeNewswire

Immatics Appoints Venkat Ramanan as Chief Financial Officer

Immatics N.V. announced the appointment of Venkat Ramanan, Ph.D. as its new Chief Financial Officer, replacing Arnd Christ. Dr. Ramanan brings over 25 years of biopharmaceutical finance experience from companies like Seagen, Gilead Sciences, and Amgen.

10/01/2025, 7:00 AM • GlobeNewswire